BeiGene Clinical Pipeline - Hematology

 PDF   1   05/2021

For more information about this resource, please submit a medical information request.

We are advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. We have three internally-developed late-stage clinical drug candidates, four marketed products in China and one marketed product in the U.S.

Rating

Rate this resource

Nice to see you!

For newest details on our EHA materials in a personal video meeting, please click here!
Service